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Abstract: Metallothionein (MT) is a highly conserved, low-molecular-weight, cysteine-rich protein that occurs in 4 isoforms 
(MT-I to MT-IV), of which MT-I+II are the major and best characterized proteins.
This review will focus on mammalian MT-I+II and their functional impact upon cellular survival and death, as seen in 
two rather contrasting pathological conditions: Neurodegeneration and neoplasms. MT-I+II have analogous functions includ-
ing: 1) Antioxidant scavenging of reactive oxygen species (ROS); 2) Cytoprotection against degeneration and apoptosis; 
3) Stimulation of cell growth and repair including angiogenesis/revascularization, activation of stem/progenitor cells, and 
neuroregeneration. Thereby, MT-I+II  mediate neuroprotection, CNS restoration and clinical recovery during neurodegen-
erative disorders. Due to the promotion of cell survival, increased MT-I+II levels have been associated with poor tumor 
prognosis, although the data are less clear and direct causative roles of MT-I+II in oncogenesis remain to be identiﬁ  ed.
The MT-I+II molecular mechanisms of actions are not fully elucidated. However, their role in metal ion homeostasis 
might be fundamental in controlling Zn-dependent transcription factors, protein synthesis, cellular energy levels/metabolism 
and cell redox state.
Here, the neuroprotective and regenerative functions of MT-I+II are reviewed, and the presumed link to oncogenesis is 
critically perused.
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Introduction
Metallothionein (MT) is a low-molecular-weight (6–7 kDa), nonenzymatic and metal-binding protein 
that is well conserved in the animal kingdom. Mammalian MT constitutes a superfamily of proteins 
that all belong to class I MTs, of which four isoforms (MT-I, MT-II, MT-III and MT-IV) have been 
identiﬁ  ed so far. They are all encoded by a family of genes located in humans on chromosome 16q13, 
where at least 16 MTs have been identiﬁ  ed, and these were primarily grouped into isoforms MT-I
and -II (MT-I+II) (Karin et al. 1984; Vallee, 1995; Kägi and Kojima, 1987; Vasak, 2005).
Although it is not consistently regarded as a ﬁ  fth MT isoform, the testis-speciﬁ  c protein tesmin was 
described as a MT-like protein and named MT-like 5. But time will show if and how many additional 
MT isoforms exist in mammals (Vallee, 1995; Dincer et al. 1999; Klaassen et al. 1999; Ghoshal and 
Jacob, 2001; Mocchegiani et al. 2005; Vasak, 2005).
MT-I-II are the best characterized MTs and have been known for almost 50 years since Margoshes 
and Vallee (1957) identiﬁ  ed a cadmium-containing protein in equine kidneys. In the 1990´s, MT-III and 
MT-IV were found, but these isoforms are poorly characterized and the data have been rather divergent 
for MT-III, while MT-IV has only been studied in the skin epidermis (Hidalgo et al. 2001; Vasak, 2005; 
Aschner and West, 2005). However, the data indicate that MT-III roles in the brain are signiﬁ  cantly 
different from those of MT-I+II (Chung and West, 2004; Vasak, 2005; Penkowa et al. 2006b). 
This review will only describe the MT-I+II proteins, which are regulated and expressed coordinately 
(Searle et al. 1984), and in mammals they have analogous biological functions (Chung and West, 2004; 
Penkowa et al. 2006b).
MT-I+II Structural Properties
The mammalian MT-I+II are composed of 61 and 62 amino acids, respectively, which are character-
ized by a lack of aromatic amino acids and histidine as well as high contents of cysteines (20 out of
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61 amino acids are cysteines ~ 30%) that form 
metal thiolates by their sulfhydryl groups, and also, 
MT-I+II contain up to 14% lysine plus arginine 
(Vallee, 1995; Klaassen et al. 1999; Ghoshal and 
Jacob, 2001; Hidalgo et al. 2001; Mocchegiani
et al. 2005; Vasak, 2005). 
The cysteine residues appear in conserved 
Cys-Xn-Cys motifs, where X is any other amino 
acid than cysteine (Vallee, 1995; Klaassen et al. 
1999; Ghoshal and Jacob, 2001; Vasak, 2005). 
The cysteine thiol (SH-)group of the metal-free 
protein (apothionein) can complex 7 divalent 
or 12 monovalent metal ions per MT molecule 
(Fig. 1), and this binding of metals is required for the 
folding and the ﬁ  nal three-dimensional conformation 
of MT resulting in a molecule with two native metal 
thiolate clusters residing in two separate globular 
domains, the C-terminal α-domain and N-terminal 
β-domain linked by a short bridging region (Vallee, 
1995; Klaassen et al. 1999; Ghoshal and Jacob, 
2001; Maret, 2002; Romero-Isart and Vasak, 2002; 
Blindauer and Sadler, 2005; Vasak, 2005). The metal 
thiolate clusters of MT-I+II also confers molecular 
stability and reduces signiﬁ  cantly the susceptibility 
to degradation (Klaassen et al. 1994; Miles, 2000). 
This is also reﬂ  ected by the fact that apothionein is 
rather unstable and is rapidly degraded and excreted, 
while in rodents Zn-loaded MT has a halftime of up 
to 18–22 hours (Jiang et al. 1998; Klaassen et al. 
1994; Miles et al. 2000).
The three-dimensional structure was revealed 
decades ago and in principle by using X-ray 
crystallography and NMR spectroscopy. The 
described isoform was mammalian MT-II loaded 
with divalent metal ions, which by both the NMR 
and crystal structure showed similar metal thiolate 
cluster conformation and practically an identical 
polypeptide folding (Romero-Isart and Vasak, 
2002; Vasak, 2005). Additional NMR studies 
validated that binding of either Zn or/and Cd ions 
would both lead to an identical MT conformation. 
Besides, the NMR solution structure of mouse MT-I 
versus MT-II showed that these isoforms display 
a high degree of similarity, as the only signiﬁ  cant 
difference between MT-I and MT-II was the level 
of β-domain ﬂ  exibility (Romero-Isart and Vasak, 
2002; Vasak, 2005).
The high amounts of cysteine including sulphur 
allow MT to bind diverse metals such as (but not 
restricted to) Zn, Cu, Cd, Hg, Pb, Ni and Co (Haq 
et al. 2003; Kelly and Palmiter, 1996; Klaassen
et al. 1999; Vasak, 2005). The 20 cysteine residues 
are distributed in the MT domains, showing 11 
cysteines in the α-domain (amino acid residues 
33–61) that can bind four divalent or six monova-
lent metals; and 9 cysteines in the β-domain (amino 
acids 1–29) capable of binding three divalent or six 
monovalent metals (Klaassen et al. 1999; Hidalgo 
et al. 2001; Romero-Isart and Vasak, 2002; Vasak, 
2005).
Figure 1. Drawing of the mammalian MT-II protein showing the two metal-thiolate clusters (C-terminal α-domain and N-terminal β-domain) 
including the 20 cysteine residues   and their sulphur atoms (S), which bind to divalent or monovalent cations (in this case Zn). The domains 
are linked by a short peptide containing amino acid residues 30–32 in mammalian MT-II LINK. In the β-domain, 3 divalent or 6 monovalent 
metal ions are coordinated, while in the α-domain 4 divalent or 6 monovalent cations can be bound. 
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MT-I+II Functional Aspects
During physiological conditions, an essential role 
of MTs still remains elusive despite extensive 
studies, however it is generally acknowledged that 
they are important for some intracellular processes 
including the ability to regulate metals including 
donation and transport of essential metals to other 
proteins and enzymes (as reviewed by Davis and 
Cousins, 2000; Miles, 2000; Palmiter, 1998). 
Interest in the role of MT-I+II is growing due 
to their possible roles in cell survival versus death, 
and particularly in the brain, MT-I+II may provide 
new therapeutic agents to be used against neurode-
generative diseases (for review see: Aschner and 
West, 2005; Chung and West, 2004). 
These roles were originally identiﬁ  ed in the brain 
by using genetically MT-modiﬁ  ed mice in combi-
nation with an experimental model of brain injury 
(Penkowa et al. 1999). The application of pathology 
is today considered as a prerequisite in order to 
detect any major changes in vivo of MT-I+II genetic 
deﬁ  ciency (for review see: Hidalgo et al. 2002; West 
et al. 2004). Thus, MT-I+II knockout (MT-KO) 
mice that are not subjected to a brain injury appear 
rather unaffected and develop normally (Michalska 
and Choo, 1993). Accordingly, in healthy physi-
ological conditions, MT-I+II are considered to be 
rather negligible or have rich compensatory backup 
molecules. However, the MT-KO mice were more 
susceptible to cadmium toxicity relative to wildtype 
control mice (Masters et al. 1994).
In case a brain injury is applied, it is evident 
that MT-I+II have neurotrophic and protective 
actions enhancing neuronal survival, brain tissue 
remodeling and repair (Aschner and West, 2005; 
Penkowa, 2006). Even if the precise molecular 
mechanisms of MT-I+II actions are not yet clari-
ﬁ  ed, some factors and intracellular processes are 
known to be altered or regulated by MT-I+II, and 
these include (but are not restricted to): Metal ion 
homeostasis, scavenging of ROS, and inhibition of 
pro-apoptotic mechanisms like caspases and p53. 
These aspects of MT-I+II biology are the focus of 
this review.
However, MT-I+II exert additional and rather 
wide-ranging functions in pathology and conse-
quently engage in processes such as protein-protein 
and protein-nucleotide interactions, regulation of 
transcription factors, mitochondrial respiration, 
thermogenesis, body energy metabolism, angio-
genesis, cell cycle progression, and cell differentia-
tion. Some of the MT-I+II molecular mechanisms 
and signaling pathways have been identiﬁ  ed and 
as they have recently been reviewed by different 
groups, we kindly refer to these (Aschner and West, 
2005; Chung and West, 2004; Penkowa, 2006; 
Vasak, 2005; West et al. 2004).
Metal Ion Homeostasis
In the brain, dysregulation of essential metals 
is associated with a number of diseases and 
neuropathologies including stroke, epilepsy, 
traumatic brain injury, neurodegenerative disor-
ders like Parkinson’s disease and Alzheimer’s 
disese (Andrews, 2000; Frederickson et al. 2004; 
Hidalgo et al. 2001, 2002). MT-I+II function as a 
metal ion buffer as they can release the bound metal 
ions, whereby MTs have important roles in metal 
homeostasis. This is most likely to contribute to 
the described MT-I+II cytoprotection (Kägi and 
Kojima, 1987; Kelly and Palmiter, 1996; Mocche-
giani et al. 2005; Penkowa, 2006). 
By acting both as a donor and acceptor of essen-
tial metals Zn and Cu, MT-I+II can direct Zn- and 
Cu-dependent proteins, enzymes, and transcrip-
tions factors in cells (Blindauer and Sadler, 2005; 
Davis and Cousins, 2000; Ghoshal and Jacob, 
2001; Kelly et al. 1996; Maret, 2002; Romero-Isart 
and Vasak, 2002; Ye et al. 2001).
In mammals, the Zn regulation by MT-I+II is 
likely of major importance, since Zn is essential for 
many cellular functions (Maret, 2002; Mocchegiani 
et al. 2005; Vasak, 2005; Ye et al. 2001). However, 
a deﬁ  ciency or overload with Zn is cytotoxic, and 
Zn-related diseases like acrodermatitis entero-
pathica and the lethal milk syndrome may occur. 
Especially the brain is susceptible to dysregulated 
Zn concentrations that cause severe neuronal 
damage (Kelly et al. 1996; Frederickson et al. 
2004). When Zn is lowered such as seen during a 
dietary insufﬁ  ciency, MT-I+II will usually release 
the Zn and thereby become degraded leading to 
signiﬁ  cantly decreased MT-I+II expression levels 
(Hidalgo et al. 2002), not only in peripheral tissues 
but also in the brain tissue. During conditions with 
excess Zn in the brain, MT-I+II mRNA and protein 
are increased in order to bind and neutralize the 
metals (Kelly et al. 1996; Miles et al. 2000; Hidalgo 
et al. 2002; Haq et al. 2003).
Metal Transfer and Redox Potential
Moreover, MT-I+II can transfer Zn to other metal-
containing molecules like enzymes, antioxidant 
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factors, Zn-ﬁ  nger proteins and transcription factors, 
which also are essential for several signaling 
pathways and for the cell fate (Frederickson et al. 
2004; Klaassen et al. 1999; Maret, 2002; Maret,
et al. 2002; Ye et al. 2001). This may occur directly 
by protein-protein interactions leading to a direct 
transfer of Zn from MT-I+II to mitochondrial 
aconitase (Feng et al. 2005).
Metals are also released from the thiolate 
clusters when MT-I+II are oxidized by constitu-
tive, mild pro-oxidant factors such as glutathione 
disulﬁ  de (GSSG) or selenium compounds (Ye et al. 
2001; Maret, 2002; Khatai et al. 2004). In the cells, 
disulﬁ  des such as GSSG can oxidize MT proteins 
leading to an immediate Zn release, whereas the 
glutathione (GSH) reduces the protein leading to 
a reuptake of the available Zn (Chen and Maret, 
2001). 
In fact, the glutathione (GSH)/GSSG redox pair 
can cooperate with MT/apothionein in order to 
coordinate the uptake and release of metals from
the MT thiolates (Chen and Maret, 2001; Romero-
Isart and Vasak, 2002). Another contributor to the 
release of metals from MTs is reactive oxygen and 
nitrogen species (ROS), which is part of the MT-I+II 
antioxidant mechanism of action. In general, ROS 
attack and oxidize the metal-thiolate clusters, and 
subsequently MT-I+II release their metals, which 
may be complexed again in case of reductive condi-
tions and if the proper metals are provided (Romero-
Isart and Vasak, 2002). However, it has also been 
reported by Feng et al. (2006) that MT-I+II can 
form intramolecular disulﬁ  de bonds in vivo, which 
increase after the release of the metal ions.
Scavenging of Free Radicals
Oxidative stress refers to the cytotoxic conse-
quences of a mismatch between the formation of 
ROS and the ability of the cells to produce antioxi-
dants. During stressful and/or pathological condi-
tions, pro-inﬂ  ammatory responses and particularly 
activated leukocytes increase ROS generation 
signiﬁ  cantly, and accordingly, inﬂ  ammation is 
regularly followed by oxidation and/or nitration 
of lipids, proteins, DNA and carbohydrates  (Allan 
and Rothwell, 2003; Espejo et al. 2005; Hidalgo et 
al. 2002; Mhatre et al. 2004; Penkowa and Hidalgo, 
2001, 2003; Penkowa et al. 2005). Oxidative stress 
is a major inducer of apoptotic cell death and thus 
has major pathogenic roles in most degenerative 
disorders  (Allan and Rothwell, 2003; Andrews, 
2000; Hidalgo et al. 2002). Also, generation of 
oxidative stress is the mode of action of most 
anti-cancer therapies and cytotoxicity (Kondo
et al. 1997; Klaassen et al. 1999; Theocharis et al. 
2003). 
In the 1980’s, Thornalley and Vasak, (1985) 
showed in a cell free system that MT-I is an efﬁ  -
cient ROS scavenger that inhibits ROS-induced 
cyto- and nuclear toxicity more effectively than 
proteins 10–50-times its molecular weight. Since 
then, numerous in vitro studies have conﬁ  rmed 
the MT-I+II antioxidant effects and also, it was 
shown that MT-I+II scavenge ROS with higher 
molar effectiveness than glutathione (Abel and de 
Ruiter, 1989; Cai and Cherian, 2003). 
By using genetically modiﬁ  ed cells, it became 
clear that MT-I overexpression protects against 
ROS cytotoxicity and vice versa in MT-I+II deﬁ  -
cient cell cultures (Kondo et al. 1997; Klaassen
et al. 1999; Wanpen et al. 2004).
As shown in animal models of various brain 
disorders, MT-I+II can also inhibit in vivo oxida-
tive stress efficiently, where MT-I+II prevent 
ROS-mediated toxicity such as lipid peroxidation, 
protein tyrosine nitration due to peroxynitrite,
and NO formation, which ultimately lead to
neuronal degeneration and apoptotic cell death
(Ebadi et al. 2005a, b; Gong and Elliott, 2000; Hidalgo
et al. 2001, 2002; Nagano et al. 2001; Penkowa
et al. 2006a,b; West et al. 2004). This alone, 
makes the MT-I+II antioxidant actions have a high 
impact upon brain dysfunctioning and cell death, 
but as described below, MT-I+II also have direct 
anti-apoptotic actions (Fig. 2), which become 
signiﬁ  cantly important during CNS pathologies 
and in case of tumor growth including resistance 
to anti-cancer therapy.
From a number of in vitro and in vivo studies, 
it was shown that MT-I+II readily react with 
hydroxyl, superoxide, and nitric oxide; while the 
MT-I+II thiol groups can bind peroxynitrite anion 
and peroxynitrous acid (Aschner and West, 2005; 
Penkowa, 2006; Romero-Isart and Vasak, 2002). 
In yeast, increased MT-I+II levels were suggested 
to functionally compensate for deﬁ  ciency of Cu/
Zn-super oxide dismutase (Cu/Zn-SOD) in the 
defense against oxidative stress (Tamai et al. 1993). 
Moreover, MT-I+II induction may antagonize the 
deleterious effects of oxidative stress on catalase 
(Haidara et al. 1999). 
In case of glutathione depletion, MT-I+II enrich-
ment of cells can confer profound resistance towards 
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oxidative damage (Min et al. 2005). As described 
above, MT-I+II may donate and accept metals from 
the GSSG/GSH system, and also during oxidative 
stress, MT-I+II interact with this system in order to 
inhibit GSH depletion (Jiang et al. 1998; Haidara 
et al. 1999). In this regard, it was reported that the 
α- and β-domains of MT-I+II may react differently 
to ROS exposure, even if the two domains appear 
rather similar. Hence, the N-terminal β-domain 
of MT-I would rapidly release all the complexed 
metals and form disulﬁ  de bonds after exposure 
to NO, while in contrast the C-terminal α-domain 
remained unaffected (Romero-Isart and Vasak, 
2002; Feng et al. 2005). This indicates that the
MT-I+II biological reactions are complex and deserve 
further attention, with the purpose of advancing the 
understanding of its functional properties.
Inhibition of Apoptosis
Numerous in vitro, in vivo and human studies have 
shown anti-apoptotic actions of MT-I+II, although 
the actual mechanisms of action remain to be fully 
clariﬁ  ed.
First, MT-I+II are metal ion chelators, and 
they have signiﬁ  cant antioxidant and anti-inﬂ  am-
matory actions, which may mediate the anti-
apoptotic actions of MT-I+II (Aschner and West 
2005; Penkowa et al. 2006). As pro-inﬂ  ammatory 
responses including neurotoxic cytokines like 
interleukins and tumor necrosis factor-α (TNFα) 
can induce neuronal apoptosis per se, the MT-I+II 
reduction of brain inﬂ  ammation may contribute to 
their protective effects.
However, it is not likely that these effects of 
MT-I+II provide all the answers, and particularly 
as mounting data have shown direct anti-apoptotic 
actions of MT-I+II (Chung et al. 2003; Køhler
et al. 2003).
MT-I+II interact with a range of molecular 
pathways that directly or indirectly regulate the 
apoptotic cascade. A number of experiments have 
focused on the MT-I+II inhibition of the mitochon-
drial cytochrome-c release and the activation of 
caspase-3 (Fig. 2) (Ceballos et al. 2003; Cherian 
and Apostolova, 2000; Gong and Elliott, 2000; 
Giralt et al. 2002; Nagano et al. 2001; Penkowa
et al. 2004,2005; Stankovic, 2005). The cyto-
chrome-c outﬂ  ow from the mitochondria is critical 
as an initiator of ROS-triggered formation of the 
apoptosome; which is followed by pro-caspase-3 
cleavage generating active caspase-3, the execu-
tioner of the apoptotic death process (Potashkin and 
Meredith, 2006). During pro-apoptotic conditions, 
MT-I+II cause a signiﬁ  cant reduction in the cyto-
chrome-c leakage into the cytoplasm and reduced 
levels of caspases (e.g. caspase-1 and -3), although 
the precise molecular mechanism of action has not 
been clariﬁ  ed (Carrasco et al. 2000; Cherian and 
Apostolova, 2000; Espejo et al. 2005; Gong and 
Elliott, 2000; Giralt et al. 2002; Nagano et al. 2001; 
Penkowa et al. 2004,2005; Penkowa and Hidalgo, 
2001; Stankovic, 2005).
Another key inducer of apoptosis is the tumor 
suppressor protein p53, which is efﬁ  ciently coun-
tered by MT-I+II by means of a direct interaction 
as shown by Ostrakhovitch et al. (2006). Hence, 
MT-I+II cause a p53-null state that accelerates 
tumor cell growth and survival (Ostrakhovitch
et al. 2006).
Furthermore, nucleotides ATP and GTP are 
ligands that bind to MT-I+II (Jiang et al. 1998; 
Maret, 2002; Maret et al. 2002; Vallee, 1995) leading 
to changes in MT-I+II structural and functional 
Figure 2. Oxidative Stress and Secondary Damage. ROS scavengers MT-I+II inhibit oxidative stress, in part due to their metal ion release. 
MT-I+II also counter apoptosis directly, e.g. through inhibition of cytochrom c leakage and caspase-3 activation.
Biomarker Insights 2006:1104
Penkowa et al
properties (Maret et al. 2002). Also, MT-I+II and 
ATP levels are correlated, which in itself could 
indicate a role in cell loss or survival, since ATP 
depletion is part of the apoptotic signal cascade 
(Aschner and West, 2005; Ebadi et al. 2005a). 
The link between MT-I+II and ATP could also 
indicate other actions, such as a recently reported 
stabilization and restoration of the ageing mito-
chondrial genome by MT-I+II (Ebadi et al. 2005a), 
as well as the MT-I+II roles in energy balance 
and metabolism as mediated by interactions with 
mitochondrial factors like m-aconitase (Beattie
et al. 1998; Haq et al. 2003; Ye et al. 2001). 
Another possible anti-apoptotic mechanism 
of MT-I+II could be the reported interaction with 
transcription factor nuclear factor KappaB (NFκB), 
as MT-I+II control the cellular concentration and 
activity level of NFκB, which is implicated in 
both cell death and survival (Carrasco et al. 2000; 
Crowthers et al. 2000).
In a dose-dependent manner, MT-I+II also 
increase de novo synthesis and expression
levels of common proto-oncogenes (e.g. c-myc), 
apoptosis-inhibitory genes (e.g. bcl-2) and a 
number of growth/trophic factors (like FGF, TGFβ, 
VEGF, BDNF, GDNF, NTs) that are all well-known 
as promoters of cell survival (Cherian and Aposto-
lova, 2000; Ebadi et al. 2005b; Miles et al. 2000; 
Mocchegiani et al. 2005; Penkowa, 2006; Tekur 
and Ho, 2002) 
According to these functions, degeneration 
and neuron loss are all more severe in MT-I+II 
deﬁ  cient mice (MT-I+II knock-out (MT-I+IIKO) 
mice) than in wildtype controls, whilst the disor-
ders are efﬁ  ciently diminished by transgenic MT-I 
overexpression and exogenous MT-I or MT-II 




Brain pathology and neurological disorders are 
followed by acute pro-inﬂ  ammatory responses 
of microglia/macrophages and lymphocytes 
secreting cytotoxic cytokines, tissue digesting 
enzymes, complement, and ROS (Penkowa et al. 
2006a, b; Potts et al. 2006). In addition, increased 
metal ions with potential neurotoxic actions are 
seen in the damaged brain tissue, which can be 
due to a number of parameters such as cytolysis, 
pH changes, dysregulation of metal-binding 
factors, and breakdown of the blood-brain barrier 
(Andrews, 2000; Frederickson et al. 2004; Kelly 
et al. 1996). 
Though inﬂ  ammatory reactions are necessary 
for the brain tissue repair process, they also mediate 
collateral and delayed (secondary) damage to the 
brain. Particularly ROS are evidently implicated 
in secondary damage including neurodegenera-
tion and ultimately apoptotic cell death (Allan and 
Rothwell, 2003; Mhatre et al. 2004; Potashkin and 
Meredith, 2006). ROS are particularly toxic in the 
brain, as the microenvironment is characterized 
by low antioxidant capacity and high content of 
lipids (myelin) that are readily oxidized and/or 
peroxidized (Penkowa et al. 2004, 2005; Potashkin 
and Meredith, 2006; Potts et al. 2006). However, 
if the brain inﬂ  ammatory responses are severely 
suppressed, as shown in mice with genetic deﬁ  -
ciency of interleukin-6 (IL-6) or macrophage 
colony stimulating factor (M-CSF), the subsequent 
repair mechanisms and tissue remodelling may not 
occur or they are highly insufﬁ  cient (Penkowa et al. 
2002; Poulsen et al. 2005). Thus, cerebral inﬂ  am-
mation can result in neurotoxicity with progressive 
neuron death or instead, it can mediate neuropro-
tection and CNS tissue repair.
Astroglia were previously considered as merely 
passive cells, which only provided structural 
support for the neurons, as to why they were 
named glia, which means ‘glue’. Now, astroglia 
are acknowledged to be of major importance for 
neuronal development, morphology and physi-
ology including metabolism, synaptic transmis-
sion, neurovascular coupling and neuritogenesis 
(For reviews see: Darlington, 2005; Seifert et al. 
2006; Sofroniew, 2005). 
Reactive astrogliosis occurs in parallel to the 
acute pro-inﬂ  ammatory responses of microglia/
macrophages and lymphocytes (Carrasco et al. 
2000; Espejo et al. 2005; Mhatre et al. 2004; 
Penkowa et al. 2005). Recently it has become 
clear that during brain disorders, the astrocytes are 
crucial for neuronal survival, functional recovery, 
synaptic plasticity and regeneration (Penkowa
et al. 2004, 2006b; Sofroniew, 2005; Seifert et al. 
2006).
In the brain, reactive astrocytes are the main 
source of neuroprotective factors with anti-
inflammatory and/or antioxidant and/or anti-
apoptotic roles, which explains why astroglia 
are crucial for neuronal survival, growth, and 
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functioning (Mhatre et al. 2004; Penkowa et al. 
2004, 2006b; Sofroniew 2005; Seifert et al. 2006). 
Accordingly, astrocytes provide important targets 
for the development of neuroprotective drugs. In 
order to develop new therapeutic strategies, the 
major components leading to delayed brain damage 
should each be targeted (Allan and Rothwell, 2003; 
Frederickson et al. 2004; Potts et al. 2006). This 
would require a polypharmaceutical strategy with 
drugs tailored towards the inﬂ  ammatory response 
(like glucocorticoids, ibuprofen or minocycline), 
ROS formation (like SOD or glutathione peroxi-
dase), and the excess of metals (metal chelator such 
as deferoxamine).
However, a more proﬁ  cient approach would 
be to ﬁ  nd a potential drug target that includes all 
three damage-causing aspects (monotherapy). 
Such target would ideally mediate anti-inﬂ  amma-
tory and antioxidant actions and chelate (buffer) 
metal ions. In this regard, among the best known 
examples of such a drug target are MT-I+II, which 
prevent pro-inﬂ  ammatory responses in the brain, 
oxidative stress, apoptotic cell death as well as they 
regulate and buffer the levels of metals. 
In agreement with the presented MT-I+II 
actions, various brain disorders are more severe in 
MT-I+II deﬁ  cient mice than in wildtype controls, 
whilst the clinical and histopathological symptoms 
are efﬁ  ciently diminished by MT-I overexpres-
sion and exogenous MT-I or MT-II treatment 
(Aschner and West, 2005; Penkowa et al. 2006a, b). 
Hence, both endogenous and exogenous MT-I+II 
ameliorate neuroinﬂ  ammation, neurodegenera-
tion and neuronal apoptosis, as shown after brain 
injury, stroke, epilepsy, experimental autoimmune 
encephalomyelitis (EAE), amyotrophic lateral 
sclerosis (ALS), Parkinsons disease, pellagra-
dementia, malnutrition, and encephalitis (Aschner 
and West, 2005; Chung et al. 2003, 2004; Ebadi
et al. 2005a; Mocchegiani et al. 2005; Penkowa et 
al. 2006; Vasak, 2005; West et al. 2004). Gener-
ally, these data as well as studies of human brain 
tissue from neurological patients showed that apop-
tosis occurred in cells devoid of MT-I+II, while
MT-I+II expressing cells were spared from apop-
tosis (Mocchegiani et al. 2005; Penkowa, 2006; 
West et al. 2004). This indicates that MT-I+II 
by some fundamental mechanisms overrule and 
prevent cell death, despite the fact that cells were 
exposed to pro-apoptotic signals.
Also, endogenous and exogenous MT-I+II can 
activate neuroglial stem cells as part of the brain 
repair responses. During EAE-demyelination, 
oligodendroglial progenitor cells are recruited by 
MT-I+II, whereby remyelination and recovery 
are promoted (Espejo et al. 2005; Penkowa and 
Hidalgo, 2003). Neural progenitor/stem cells 
are even more responsive to MT-I+II, which 
profoundly increase cell renewal and mobilization 
from the neurogenic zone as shown in the adult 
injured brain (Penkowa et al. 2006a). 
In conclusion, MT-I+II can protect the brain 
from degeneration and cell death; while neuronal 
repair and functional recovery are improved. To 
this end, their potential for replacing lost neurons 
in the injured brain indicates a potential key role 
for MT-I+II in the future management of neuro-
logical diseases.
As listed in Table 1, MT-I+II mediate neuropro-
tection and regeneration, and thus, MT-I+II may 
provide drug targets for the development of phar-
maceuticals against neurodegenerative diseases. 
Neoplasms
The MT-I+II roles in pathophysiological processes 
like pro-inﬂ  ammatory signaling, ROS generation, 
cell degeneration and apoptosis, have led to many 
studies of MT-I+II expression during tumorigen-
esis (For review see: Theocharis et al. 2004). In 
fact, the antioxidant and anti-apoptotic roles of 
MT-I+II have in part been characterized due to 
such tumor studies, which mainly were carried 
out by exposing tumor cells with absent, unal-
tered or increased MT-I+II expression to a range 
of experimental anti-cancer therapies (Kennette
et al. 2005; Klaassen et al. 1999; Kondo et al. 1997; 
Liu et al. 1999; Miles et al. 2000; Qu et al. 2006; 
Tekur and Ho, 2002). 
Due to their cytoprotective actions, MT-I+II 
could be expected to defend neoplastic cells against 
the ROS-generating toxicity of radiation and 
chemotherapy. Accordingly, it is not surprising that
MT-I+II expression levels were reported to be 
associated with tumor cell survival and resistance to 
treatment (For reviews see: Cai and Cherian, 2003; 
Cherian et al. 1994; Theocharis et al. 2003, 2004). 
However, the vast majority of these papers have 
been descriptive, as they reported and correlated 
the pattern and extent of MT-I+II expression with 
tumor histology, grade, stage, invasiveness, and 
patients’ survival and prognosis (Cherian et al. 
1994; Kondo et al. 1997; Miles et al. 2000; Poulsen 
et al. 2006; Qu et al. 2006; Tekur and Ho, 2002). 
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These studies reported that MT-I+II expression 
levels are increased in a range of human tumors 
(e.g. tumors of the mammary gland, lung, naso-
pharynx, colon, kidney, liver, salivary gland, testes, 
ovaries, prostate, thyroid gland, bone marrow 
hematopoietic cells and bladder). The increased 
MT-I+II levels have been correlated to malignancy 
and tumorigenesis, although it is based upon 
descriptive approaches lacking more mechanistic 
models and data. In fact, any direct causative roles 
of MT-I+II in oncogenic transformation remain to 
be identiﬁ  ed.
Below, we will discuss some interesting ﬁ  ndings 
on MT-I+II in relation to tumor biology.
MT-I+II and clinical outcome - Part I
Increased expression levels of MT-I+II mRNA and 
protein have generally been coupled to cancer cell 
survival and resistance to various pro-apoptotic 
regimes including chemotherapy and radiation 
(Cherian et al. 2003; Miles et al. 2000; Kennette 
et al. 2005; Poulsen et al. 2006; Qu et al. 2006; 
Theocharis et al. 2003).
Hence, in malignant B-cell lymphomas and 
transitional cell carcinoma of the bladder, MT-I+II 
levels have been associated with worse outcome, 
as increased MT-I+II are inversely correlated to the 
patients’ survival (Poulsen et al. 2006; Yamasaki 
et al. 2006).
Also, increased MT-I+II levels are more 
frequent in high grade bladder tumors showing 
local invasion, relative to low grade, non-invasive 
tumors (Yamasaki et al. 2006).
Another study performed mRNA expression 
proﬁ  ling by using Affymetrix genechips (micro-
arrays) in diffuse large B-cell lymphomas, where 
it was shown that MT mRNA upregulation is an 
indicator of therapeutic failure (Poulsen et al. 
2006). The same study also applied histopatho-
logical analyses that revealed MT-I+II expression 
in both the non-malignant cells (macrophages) 
and ín the malignant lymphocytes; although 
only the MT-I+II of the malignant cells were 
related to the clinical outcome. Hence, when 
MT-I+II expression was found in more than 20% 
of malignant cells, the patients experienced a 
signiﬁ  cantly reduced 5-year survival (Poulsen 
et al. 2006). 
In line with this, MT-I+II can confer cytopro-
tection against anti-neoplastic regimens, which 
typically cause ROS-induced DNA damage and 
break-down leading to apoptotic cell death (Abel 
and de Ruiter, 1989; Cai and Cherian, 2003;
Tsangaris et al. 2000).
Also, MT-I+II are detected in gliomas, epen-
dymomas and in the majority of meningiomas, 
although the expression levels are not consistently 
associated with clinical outcome (For reviews 
see: Klaassen et al. 1999; Theocharis et al. 2004). 
In fact, MT-I+II levels of brain gliomas were 
low when compared to MT-I+II expression of 
surrounding, reactive astrocytes, i.e. the non-
malignant glia (Tews et al. 2000).
MT-I+II inhibitory actions
MT-I+II scavenge and neutralize ROS 
MT-I+II inhibit pro-inﬂ  ammatory cytokines, macrophages and T-lymphocytes.
MT-I+II inhibit apoptosis (incl. cytochrome-c leakage, p53 levels, caspase activity)
MT-I+II stimulatory actions
MT-I+II augment anti-inﬂ  ammatory and neuroprotective parameters in CNS
MT-I+II increase mitogens, apoptosis-inhibitory genes and growth/trophic factors
MT-I+II promote functional recovery including neurogenesis 
MT-I+II homeostatic regulation 
MT-I+II control and regulate toxic and essential metals 
MT-I+II regulate NFkB concentration and activity 
Table 1.
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Accordingly, it is likely that a reported asso-
ciation between MT-I+II and clinical outcome in 
some cases might simply reﬂ  ect the host defense 
response to tumor pathology, which includes induc-
tion of MT-I+II in order to endow cells (whether 
neoplastic or not) with potent survival mechanisms 
(Andrews, 2000; Tsangaris et al. 2000; Cherian
et al. 2003; Kennette et al. 2005). It is also note-
worthy that we lack data regarding the presumed 
role of MT-I+II in neoplastic transformation. So, a 
direct causative role of MT-I+II in pro-oncogenic 
events remains to be identiﬁ  ed.
Nevertheless, tumor resistance to pro-
apoptotic therapy represents a major problem in 
daily oncology. Since many reports did show a 
signiﬁ  cant association between increased MT-I+II 
levels and tumor progression as well as clinical 
outcome, we will now discuss the possibility of 
differential MT-I+II regulation. If tumor cell-
specific MT-I+II expression can be silenced 
without affecting the healthy bystander cells, such 
a strategy may provide a successful adjuvant to 
be used along anti-neoplastic regimens in order to 
prevent cell survival due to MT-I+II induction.
Differential MT-I+II regulation
A differential and tissue-speciﬁ  c regulation of
MT-I+II may alleviate some of the major problems 
with resistance to anti-cancer therapy. The optimum 
solution in this regard, would be to inhibit MT-I+II 
speciﬁ  cally in the malignant cells, and at the same 
time induce or not affect MT-I+II in the the healthy 
bystander tissue. Such a strategy may both counter 
the tumor resistance to treatment and the aspect 
of toxic side-effects, which are major obstacles 
to the curative treatment of cancer. Interestingly, 
the metal bismuth has been shown to induce
MT-I+II in normal (non-malignant) tissue only, 
while malignant cells remain rather unaffected 
(Cherian et al. 1994, 2003). This may be due to the 
fact that bismuth accumulates in the healthy cells, 
while it is poorly taken up by transformed cells, 
although it is unclear how bismuth distinguishes 
between healthy versus malignant cells.
However, it was shown that bismuth affects 
different glycolytic enzymes and metabolites 
that have housekeeping and physiological roles 
(Magnusson et al. 2005). Such parameters and their 
signaling may indeed be disturbed in neoplastic 
cells, which could explain their poor import of 
bismuth.
To this end, Magnusson et al. (2005) propose 
that the bismuth mechanisms of action involve a 
“hypoxia-like” stress mimicking the molecular 
changes seen in normal cells exposed to ischemia. 
As tumor cells often show very early upregulation 
of hypoxia-induced, pro-angiogenic factors as part 
of their malignant transformation, these signaling 
pathways may already be perturbed in the tumor 
cells, which thereby have lost their import mecha-
nism for bismuth (Cai and Cherian, 2003; Kennette 
et al. 2005; Kondo et al. 2004; Theocharis et al. 
2003; Tsangaris et al. 2000). 
Accordingly, bismuth may become an adjuvant 
that maintains or increases MT-I+II expression 
only in healthy cells, which thereby are defended 
against ROS-generation and cytotoxicity caused 
by radiation or chemotherapy. At the same time, 
the malignant cells likely remain unaffected by 
bismuth, as to why these cells may still be targeted 
by anti-neoplastic strategies.
Within this context, bismuth administration 
shows a promising potential and since it is already 
being used in the clinic, it may be more readily 
applicable as a pharmaceutical. 
However, with new technologies and improved 
scientiﬁ  c equipment, we envisage that very soon 
other approaches will emerge. These may likely 
include new disciplines such as gene-directed 
techniques, small interference RNA-based regula-
tion, tumor cell-speciﬁ  c transcriptomics, metabolo-
mics including the potential to control metabolite 
degradation or turnover rate, and organ-targeted 
control of cell differentiation and cell replacement 
strategies.
MT-I+II and clinical outcome - Part II
In this second part, we will brieﬂ  y introduce some 
recent data, which indicate that increased MT-I+II 
levels are correlated to either better or unaltered 
prognosis, at least in some speciﬁ  c tumor tissues 
(Theocharis et al. 2003, 2004). 
In human liver, MT-I+II expression is reduced 
in neoplastic cells as shown during carcinomas 
and adenocarcinoid metastases; whereas intense 
MT-I+II induction is found in the surrounding 
healthy cells (Cherian et al. 2003; Theocharis
et al. 2003). This hepatic MT-I+II downregulation 
is considered to be tumor cell-speciﬁ  c, as MT-I+II 
are increased in non-malignant cirrhotic nodules, 
which are surrounding the malignant hepatocytes 
(Theocharis et al. 2004). Recently, a signiﬁ  cant 
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hepatocellular carcinoma and in 7 different
types of hepatocellular carcinoma cell lines
(Chan et al. 2006). Hence, in human 
primary liver carcinomas, MT I tran-
scripts were repressed by more than
100-fold, as shown by using gene expression 
profiling and qRT-PCR (Chan et al. 2006). 
The same study showed that MT-I mRNA was 
reduced in both early and later stages of hepa-
tocellular cancer, whereby inactivation of MT-I 
might have an impact on tumor development 
and/or progression. 
This expression pattern is also found in some 
head and neck cancers, renal neoplasms, sarcomas 
and breast adenocarcinomas, where increased 
MT-I+II are detected speciﬁ  cally in the healthy 
bystander cells (Dutsch-Wicherek et al. 2005; 
Ishii et al. 2001; Theocharis et al. 2004), which 
suggests that increased MT-I+II levels could 
simply be part of the normal cellular response to 
tumor pathology.
In colorectal cancer, positive MT-I+II expres-
sion is connected to a favourable prognosis and 
improved outcome, as MT-I+II progressively 
diminish during oncogenic transformation of 
healthy colorectal mucosa into adenomatous polyps 
and adenocarcinoma (Theocharis et al. 2004). 
In other tissue types such as kidney and skel-
eton, MT-I+II may not inﬂ  uence tumor biology. 
Hence, the expression of MT-I+II was comparable 
in osteosarcoma patients and their healthy controls, 
and MT-I+II levels were not related to survival 
rate (Theocharis et al. 2004). Also, MT-I+II levels 
are not associated with histological type, stage of 
disease, or the prognosis of renal cell carcinomas 
(Mitropoulos et al. 2005). However, data obtained 
in kidney are not clear, since another study showed 
a 15-fold reduction in the MT-I+II levels of renal 
cancer cells relative to surrounding healthy cells 
(Ishii et al. 2001), while MT-I+II induction in renal 
neoplasms may also relate to a poor prognosis and a 
malignant behavior of the renal tumor, as discussed 
by Theocharis et al. (2004).
MT-I+II in neoplasms: Friend or Foe? 
From the current data, it is unknown whether MT-
I+II are involved in malignant transformation, or if 
the observed changes in MT-I+II are epiphenomena 
caused by the general neoplastic pathology. To this 
end, it is likely of high importance to distinguish 
between MT-I+II expression in the malignant cells 
versus healthy bystander cells, as the latter may 
likely alter their MT-I+II in their general response 
to neoplastic pathology (Dutsch-Wicherek et al. 
2005; Ishii et al. 2001; Poulsen et al. 2006). 
Accordingly, increased MT-I+II levels in the 
healthy cells surrounding the tumor may represent 
a host defense mechanism as seen in other non-
neoplastic pathologies.
Overall, an intricate variety of gene expression 
changes are seen during carcinogenesis and these 
include activation of proto-oncogenes, mitogens 
and genes critical to regulation of growth and 
survival of cells. During this, the cells require 
essential metals like Zn, which is needed for Zn-
dependent transcription factors, enzymes, and Zn-
ﬁ  nger proteins (Hidalgo et al. 2001, 2002; Vallee, 
1995; Vasak, 2005). The altered Zn requirements 
alone, but also an altered gene expression proﬁ  le 
may explain why MT-I+II expression has changed 
in some tumor cells. The fact that MT-I+II are 
rapidly induced by any kind of pathology or stress 
may also contribute to the MT-I+II increases found 
in some tumor cells. This indicates that increased 
MT-I+II levels are not necessarily reﬂ  ecting caus-
ative roles for MT-I+II in tumorigenesis. 
Moreover, the profound variation in MT-I+II 
expression between tumors may simply reﬂ  ect 
general differences in the biological behavior of 
the neoplasms. Hence, tumors showing highly 
increased MT-I+II together with malignant 
behavior might represent tissues that in general 
show high protein turnover and/or high pro-
angiogenic activity and/or proliferation rates. Even 
though such features may obviously provide tumor 
cells with resistance to radiation and chemotherapy 
(Cherian et al. 1994, 2003; Theocharis et al. 2003, 
2004), they are not indicating mechanistic roles of 
MT-I+II in carcinogenesis.
In general, cell cultures and animals with 
genetic MT-I+II deﬁ  ciency are more susceptible 
to radiation- and chemotherapy-induced cell death 
than wildtype controls or transgenic MT-I overex-
pressors (Andrews, 2000; Klaassen et al. 1999). In 
wildtype animals with intact MT-I+II genes, exper-
imental Zn treatment rapidly induces MT-I+II and 
protects against cell death caused by anti-cancer 
therapy (Kennette et al. 2005). However, the Zn 
treatment gave the same protection against anti-
cancer therapy in MT-I+II deﬁ  cient mice, which 
suggests that resistance to anti-neoplastic treatment 
is due to other Zn-induced factors than MT-I+II 
(For review see: Klaassen et al. 1999).
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Biomarker Insights 2006:1 Together, these data indicate that MT-I+II alone 
are not responsible for tumor cell-speciﬁ  c resis-
tance to anti-neoplastic treatments. 
Accordingly, it is impossible, at least at the 
moment, to define MT-I+II as biomarkers of 
prognosis or clinical outcome in relation to 
neoplasms.
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